307 related articles for article (PubMed ID: 16185941)
1. Targeting malaria with specific CDK inhibitors.
Geyer JA; Prigge ST; Waters NC
Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
[TBL] [Abstract][Full Text] [Related]
2. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
[TBL] [Abstract][Full Text] [Related]
3. Structural model of the Plasmodium CDK, Pfmrk, a novel target for malaria therapeutics.
Peng Y; Keenan SM; Welsh WJ
J Mol Graph Model; 2005 Sep; 24(1):72-80. PubMed ID: 16046158
[TBL] [Abstract][Full Text] [Related]
4. Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases.
Woodard CL; Li Z; Kathcart AK; Terrell J; Gerena L; Lopez-Sanchez M; Kyle DE; Bhattacharjee AK; Nichols DA; Ellis W; Prigge ST; Geyer JA; Waters NC
J Med Chem; 2003 Aug; 46(18):3877-82. PubMed ID: 12930149
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones.
Geyer JA; Keenan SM; Woodard CL; Thompson PA; Gerena L; Nichols DA; Gutteridge CE; Waters NC
Bioorg Med Chem Lett; 2009 Apr; 19(7):1982-5. PubMed ID: 19250824
[TBL] [Abstract][Full Text] [Related]
6. Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors.
Keenan SM; Geyer JA; Welsh WJ; Prigge ST; Waters NC
Comb Chem High Throughput Screen; 2005 Feb; 8(1):27-38. PubMed ID: 15720195
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development.
Waters NC; Geyer JA
Expert Opin Ther Targets; 2003 Feb; 7(1):7-17. PubMed ID: 12556199
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.
Keenan SM; Welsh WJ
J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982
[TBL] [Abstract][Full Text] [Related]
9. Identification of an effector protein and gain-of-function mutants that activate Pfmrk, a malarial cyclin-dependent protein kinase.
Chen Y; Jirage D; Caridha D; Kathcart AK; Cortes EA; Dennull RA; Geyer JA; Prigge ST; Waters NC
Mol Biochem Parasitol; 2006 Sep; 149(1):48-57. PubMed ID: 16737745
[TBL] [Abstract][Full Text] [Related]
10. In silico three-dimensional pharmacophores for aiding the discovery of the Pfmrk (Plasmodium cyclin-dependent protein kinases) specific inhibitors for the therapeutic treatment of malaria.
Bhattacharjee AK
Expert Opin Drug Discov; 2007 Aug; 2(8):1115-27. PubMed ID: 23484876
[TBL] [Abstract][Full Text] [Related]
11. Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.
Caridha D; Kathcart AK; Jirage D; Waters NC
Bioorg Med Chem Lett; 2010 Jul; 20(13):3863-7. PubMed ID: 20627564
[TBL] [Abstract][Full Text] [Related]
12. Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum.
Waters NC; Woodard CL; Prigge ST
Mol Biochem Parasitol; 2000 Mar; 107(1):45-55. PubMed ID: 10717301
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk.
Woodard CL; Keenan SM; Gerena L; Welsh WJ; Geyer JA; Waters NC
Bioorg Med Chem Lett; 2007 Sep; 17(17):4961-6. PubMed ID: 17588749
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity.
Vyas VK; Qureshi G; Ghate M; Patel H; Dalai S
SAR QSAR Environ Res; 2016 Jun; 27(6):427-40. PubMed ID: 27310104
[TBL] [Abstract][Full Text] [Related]
15. Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization.
Li JL; Robson KJ; Chen JL; Targett GA; Baker DA
Eur J Biochem; 1996 Nov; 241(3):805-13. PubMed ID: 8944769
[TBL] [Abstract][Full Text] [Related]
16. Identification of new promising Plasmodium falciparum superoxide dismutase allosteric inhibitors through hierarchical pharmacophore-based virtual screening and molecular dynamics.
Araujo JSC; de Souza BC; Costa Junior DB; Oliveira LM; Santana IB; Duarte AA; Lacerda PS; Dos Santos Junior MC; Leite FHA
J Mol Model; 2018 Jul; 24(8):220. PubMed ID: 30056475
[TBL] [Abstract][Full Text] [Related]
17. 3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum.
Kumari M; Chandra S; Tiwari N; Subbarao N
BMC Struct Biol; 2016 Aug; 16():12. PubMed ID: 27534744
[TBL] [Abstract][Full Text] [Related]
18. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
[TBL] [Abstract][Full Text] [Related]
19. The malarial CDK Pfmrk and its effector PfMAT1 phosphorylate DNA replication proteins and co-localize in the nucleus.
Jirage D; Chen Y; Caridha D; O'Neil MT; Eyase F; Witola WH; Mamoun CB; Waters NC
Mol Biochem Parasitol; 2010 Jul; 172(1):9-18. PubMed ID: 20332005
[TBL] [Abstract][Full Text] [Related]
20. Exploring structural requirements for a class of nucleoside inhibitors (PfdUTPase) as antimalarials: first report on QSAR, pharmacophore mapping and multiple docking studies.
Ojha PK; Roy K
Comb Chem High Throughput Screen; 2013 Nov; 16(9):739-57. PubMed ID: 23701009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
